• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Media releases
  • PolyPeptide announces results of the annual General Meeting 2024

PolyPeptide announces results of the annual General Meeting 2024

10 April 2024
Media releases

Baar, 10 April 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced that the shareholders approved all proposals put forward by the Board of Directors at the Company’s third annual General Meeting with a large majority.

The Chair of the Board of Directors of PolyPeptide Group AG (the “Company”), Peter Wilden, welcomed the shareholders at the Company’s third annual General Meeting (“AGM 2024”) that took place at the Chollerhalle, Zug. At the AGM 2024, a total of 25,104,023 shares with voting rights were represented, corresponding to 75.79% of the issued registered shares of the Company.

All six members of the Board of Directors proposed for re-election were appointed for a term of office ending at the conclusion of the next annual General Meeting 2025. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2025.

The shareholders also approved the Board of Directors’ proposal to delete art. 25 para. 3 of the Company’s Articles of Association relating to the aggregate compensation for consulting services to the Company provided by members of the Board of Directors.

Further proposals of the Board of Directors that were approved at the AGM 2024 included, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders also granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2023 for their
activities in the financial year 2023. The shareholders approved the Management Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2023 as well as the Remuneration Report 2023 and the report on non-financial matters for the financial year 2023, both in separate consultative votes.

The minutes of the AGM 2024 will be available here within 15 days. The next annual General Meeting 2025 will be held on 9 April 2025. […]

Download PDF (English)

Download PDF (German)

Back to news

Related posts

9 April 2025

PolyPeptide announces results of the annual General Meeting 2025


Read more
18 March 2025

PolyPeptide publishes invitation to the annual General Meeting 2025


Read more
13 January 2025

Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers